Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
about
Management of patients with unstable angina / non-ST-elevation myocardial infarction: a critical review of the 2007 ACC /AHA guidelinesAcute management of unstable angina and non-ST segment elevation myocardial infarctionEfficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysisPharmacotherapy in the cardiac catheterization laboratory: evolution and recent developmentsMeasuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical reviewThe "smoker's paradox" in patients with acute coronary syndrome: a systematic reviewGuidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolismTherapeutic approaches in arterial thrombosisEnoxaparin injection for the treatment of high-risk patients with non-ST elevation acute coronary syndromeNormalization of platelet reactivity in clopidogrel-treated subjectsSelecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention.Acute coronary syndromes: diagnosis and management, part ILow-molecular-weight heparins as adjunctive therapy to thrombolytics: extracting the best data.Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudinNovel multi-modal strategies to promote brain and spinal cord injury recovery.Study of the Efficacy, Safety and Tolerability of Low-Molecular-Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients with Embolic Stroke due to Atrial Fibrillation.Recent advances in antithrombotic therapy after acute coronary syndrome.Pharmacological and clinical differences between low-molecular-weight heparins: implications for prescribing practice and therapeutic interchange.Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The global registry of acute coronary eventsClinical review: bleeding - a notable complication of treatment in patients with acute coronary syndromes: incidence, predictors, classification, impact on prognosis, and managementHeparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome.Fondaparinux and acute coronary syndromes: update on the OASIS 5-6 studies.Rectus sheath hematoma with low molecular weight heparin administration: a case series.Safety and effectiveness of enoxaparin following fibrinolytic therapy: Results of the Acute Myocardial Infarction (AMI)-QUEBEC registryClinical benefit of low molecular weight heparin for ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitor.Bleeding risk during treatment of acute thrombotic events with subcutaneous LMWH compared to intravenous unfractionated heparin; a systematic review.Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial.Emergency cardiac surgery in patients with acute coronary syndromes: a review of the evidence and perioperative implications of medical and mechanical therapeutics.Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis.Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 YearsDosing of unfractionated heparin in acute coronary syndromes.Effect of enoxaparin on clinical events after percutaneous coronary intervention.SBC guidelines on unstable angina and non-ST-elevation myocardial infarction: executive summary.Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes.A Review of Current Diagnosis, Investigation, and Management of Acute Coronary Syndromes in Elderly Patients.Treatment of non-ST-elevation acute coronary syndrome in the elderly: current practice and future opportunities.Non ST segment elevation acute coronary syndromes: A simplified risk-orientated algorithm.Coping with new challenges in acute coronary syndromes.Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial.Newer pharmacotherapy in patients undergoing percutaneous coronary interventions: a guide for pharmacists and other health care professionals.
P2860
Q24653318-F41DD716-76B5-4A02-BB6B-FD69778BC35CQ26783157-C4CB3BB9-A070-4F89-A00A-B0B3055909D6Q26853150-56E2A441-D236-4B27-95B6-E8ECB7627D61Q26862694-F306B415-1C43-4809-8C20-1F9B030930A6Q26992262-71318E8D-D10B-48A1-A41B-0AE98D6F3FADQ27007476-0C219C1B-6DAC-4F77-9887-D03E08BF6D61Q28079081-FBE4CC92-D1A0-4615-9C87-C397B277E760Q28187576-0154F518-4B0E-4B02-9184-15E83E8539BCQ28213718-84E8CB59-788D-482E-B57A-C4DCB4828D87Q28217935-1C527E5E-479C-4C03-AFB0-10AA190A865CQ30438893-18895BDC-5A5A-4F56-8964-6A645A665FCBQ30490718-2636531A-BF51-4C0D-A0B8-152CD8AF78DFQ31039802-0F13429F-52B6-4E74-843F-FC80466625CAQ33381356-086255E1-0F12-4CDF-A518-7C7683CFE9D0Q33390906-583E0EC7-FC59-474E-AA4C-F9502544722DQ33433817-141BEE03-3BF6-4759-B2BF-AB627400B165Q33590548-0F710F44-818F-409F-8BD0-737513C22F7AQ33685447-E4703530-8D2D-4A3E-A8AE-3AA2D38665F1Q33728256-17719D70-E339-404A-88AF-F972C725E484Q33750028-0DE0D04D-97C5-4428-A334-DA7A0B8D12E6Q33750461-C28032A2-1A3D-44E4-A0A5-7F36F696E7C4Q33797609-135F3D30-6C61-4C8D-8BB9-8D3AFFFC0AD7Q34174194-07F27328-375E-46C1-BE1F-186D26682BDAQ34196711-D6171CBC-695A-41FC-9781-28BAA77EC02EQ34255603-10729E04-C1F3-40C1-BA39-CBCFE29CEC09Q34415964-285EBF96-F4B1-48A5-BA2A-CF8727259469Q34706540-86153231-D0EF-4483-AD20-39BFB029DCE2Q34716730-122AAB2D-0231-4AF1-863A-900633AC3500Q35826954-72C6CBFF-3B55-4C94-9572-71C0F41FACCCQ35883044-0C54E7F0-2203-44FB-A48B-6D70206C28E3Q35976822-8FAB89A6-1799-4F9D-914D-F97AFD625E70Q36046275-EE160DAE-4DB5-4E31-A8C3-6ABC3F718F4DQ36116996-FEBE4197-EE50-4A9D-AEA0-2D5592E62331Q36141930-257F63DB-3897-4BDA-B0F3-2F8F7A926783Q36363183-FF7BB626-DDFD-4A57-B8A7-20F20DA8E69AQ36369711-D1B9C9D0-B745-40A8-A89E-ADDC2A05117BQ36519924-CF0B0F8D-56F8-42D2-AD2A-A8A9013904A3Q36575461-D61CF2B4-692F-4454-9824-80CEC6254F63Q36608168-ABB8FADB-FAD7-47C1-B43E-1E89BBABE953Q36634214-88698703-55A9-4541-8655-17F4A03EA9BA
P2860
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Enoxaparin vs unfractionated h ...... the SYNERGY randomized trial.
@ast
Enoxaparin vs unfractionated h ...... the SYNERGY randomized trial.
@en
Enoxaparin vs unfractionated h ...... the SYNERGY randomized trial.
@nl
type
label
Enoxaparin vs unfractionated h ...... the SYNERGY randomized trial.
@ast
Enoxaparin vs unfractionated h ...... the SYNERGY randomized trial.
@en
Enoxaparin vs unfractionated h ...... the SYNERGY randomized trial.
@nl
prefLabel
Enoxaparin vs unfractionated h ...... the SYNERGY randomized trial.
@ast
Enoxaparin vs unfractionated h ...... the SYNERGY randomized trial.
@en
Enoxaparin vs unfractionated h ...... the SYNERGY randomized trial.
@nl
P2093
P50
P356
P1476
Enoxaparin vs unfractionated h ...... the SYNERGY randomized trial.
@en
P2093
Alvaro Avezum
Anatoly Langer
Carl J Pepine
Christopher C Nessel
Cindy L Grines
Dean J Kereiakes
Dietrich C Gulba
Enrique Gurfinkel
Harvey White
P356
10.1001/JAMA.292.1.45
P407
P577
2004-07-01T00:00:00Z